Immunogenicity and safety of AZD2816, a beta (B.1.351) variant COVID-19 vaccine, and AZD1222 (ChAdOx1 nCoV-19) as third-dose boosters for previously vaccinated adults: a multicentre, randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study in the UK and Poland

Míreanna comhchosúla

• Immunogenicity and safety of beta variant COVID-19 vaccine AZD2816 and AZD1222 (ChAdOx1 nCoV-19) as primary-series vaccination for previously unvaccinated adults in Brazil, South Africa, Poland, and the UK: a randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study
  de réir: Costa Clemens, SA, et al.
  Foilsithe / Cruthaithe: (2024)
• ChAdOx1 nCoV-19 (AZD1222) or nCoV-19-Beta (AZD2816) protect Syrian hamsters against Beta Delta and Omicron variants
  de réir: Neeltje van Doremalen, et al.
  Foilsithe / Cruthaithe: (2022-08-01)
• The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 beta (B.1.351) and other variants of concern in preclinical studies
  de réir: Spencer, AJ, et al.
  Foilsithe / Cruthaithe: (2022)
• The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 beta (B.1.351) and other variants of concern in preclinical studies
  de réir: Alexandra J Spencer, et al.
  Foilsithe / Cruthaithe: (2022-03-01)
• An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females
  de réir: Marchevsky, NG, et al.
  Foilsithe / Cruthaithe: (2022)